TB vaccines: The paradigms they are a-shifting

Expert Review of Vaccines

Volumn 8, Issue 12, 2009, Pages 1615-1618

  McMurray, David N ^a   Ly, Lan H ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

BACTERIAL STRAIN; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EDITORIAL; FUNDING; GENE EXPRESSION; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL SPECIALIST; MULTIDRUG RESISTANCE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NATIONAL HEALTH ORGANIZATION; NONHUMAN; PRIORITY JOURNAL; SCREENING; TUBERCULOSIS; VACCINATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION;

EID: 73849131812     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.131     Document Type: Editorial

References (24)

1. Young DB, Perkins MD, Duncan K, Barry CE 3rd. Confronting the scientific obstacles to global control of tuberculosis. J. Clin. Invest. 118(4), 1255-1265 (2008).
2. Dowdy DW, Chaisson RE. The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection. Bull. World Health Organ. 87(4), 296-304 (2009).
3. Chhabria M, Jani M, Patel S. New frontiers in the therapy of tuberculosis: fighting with the global menace. Mini Rev. Med. Chem. 9(4), 401-430 (2009).
4. Lonnroth K, Raviglione M. Global epidemiology of tuberculosis: prospects for control. Semin. Respir. Crit. Care Med. 29(5), 481-491 (2008).
5. Young D, Dye C. The development and impact of tuberculosis vaccines. Cell 124(4), 683-687 (2006).
6. Abu-Raddad LJ, Sabatelli L, Achterberg JT et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl Acad. Sci. USA 106(33), 13980-13985 (2009).
7. Barker LF, Brennan MJ, Rosenstein PK, Sadoff JC. Tuberculosis vaccine research: the impact of immunology. Curr. Opin. Immunol. 21(3), 331-338 (2009).
8. Ly LH, McMurray DN. Tuberculosis: vaccines in the pipeline. Expert Rev. Vaccines 7(5), 635-650 (2008).
9. Hernandez-Pando R, Castanon M, Espitia C, Lopez-Vidal Y. Recombinant BCG vaccine candidates. Curr. Mol. Med. 7(4), 365-372 (2007).
10. Bastos RG, Borsuk S, Seixas FK, Dellagostin OA. Recombinant Mycobacterium bovis BCG. Vaccine 27(47), 6495-6503 (2009).
11. Andersen P, Doherty TM. TB subunit vaccines - putting the pieces together. Microbes Infect. 7(5-6), 911-921 (2005).
12. Doherty TM, Dietrich J, Billeskov R. Tuberculosis subunit vaccines: from basic science to clinical testing. Expert Opin. Biol. Ther. 7(10), 1539-1549 (2007).
13. Aagaard C, Dietrich J, Doherty M, Andersen P. TB vaccines: current status and future perspectives. Immunol. Cell Biol. 87(4), 279-286 (2009).
14. Brennan MJ. The tuberculosis vaccine challenge. Tuberculosis (Edinb.) 85(1-2), 7-12 (2005).
15. Martin C. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG? Eur. Respir. J. 26(1), 162-167 (2005).
16. Hesseling AC, Johnson LF, Jaspan H et al. Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants. Bull. World Health Organ. 87(7), 505-511 (2009).
17. Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Horwitz MA. A replicationlimited recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency viruspositive persons is safer and more efficacious than BCG. Infect. Immun. 76(11), 5200-5214 (2008).
18. Whelan KT, Pathan AA, Sander CR et al. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS ONE 4(6), e5934 (2009).
19. Hawkridge A. Clinical studies of TB vaccines. Hum. Vaccin. (2009) (Epub ahead of print).
20. Izzo A, Brandt L, Lasco T, Kipnis AP, Orme I. NIH pre-clinical screening program: overview and current status. Tuberculosis (Edinb). 85(1-2), 25-28 (2005).
21. Williams A, Hatch GJ, Clark SO et al. Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb.) 85(1-2), 29-38 (2005).
22. McShane H. Vaccine strategies against tuberculosis. Swiss Med. Wkly 139(11-12), 156-160 (2009).
23. Xing Z, McFarland CT, Sallenave JM, Izzo A, Wang J, McMurray DN. Intranasal mucosal boosting with an adenovirusvectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS ONE 4(6), e5856 (2009).
24. Henao-Tamayo M, Palaniswamy GS, Smith EE et al. Post-exposure vaccination against Mycobacterium tuberculosis. Tuberculosis (Edinb.) 89(2), 142-148 (2009).